Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

A double blind study to examine the safety and efficacy of different dosages of lercanidipine in normal weight and obese patients with hypertension

• Phase: N/A

Details

• Lead Sponsor: UCB Pharma
• Treatments: Lercanidipine

Criteria

Inclusion Criteria:

• Body Mass Index (BMI): 18.0 - 24.9 or 30.0 - 39.9 kg/m2 (extremes included);

• Essential hypertension I or II WHO:

• 140 mmHg ≤ BPs ≤ 179 mmHg and BPd ≤ 109 mmHg at the end of the placebo run-in phase;

Exclusion Criteria:

• Secondary hypertension;

• Diabetes mellitus type 1, insulin dependent diabetes mellitus type 2, fasting blood glucose ≥ 160 mg/dl;

• Subjects keeping to a hypocaloric diet (except special diet for diabetics) to reduce body weight;

• History or presence of angioneurotic oedema;

• Subjects developing a hypertensive crisis during wash-out or placebo run-in period;